ADAM9 Protein, Cynomolgus, Recombinant (His)

产品编号 TMPK-00553

A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.

ADAM9 Protein, Cynomolgus, Recombinant (His)

产品编号 TMPK-00553

规格	价格	库存
100 μg	¥ 3,100	5日内发货
500 μg	¥ 12,400	5日内发货
1 mg	¥ 20,700	5日内发货

大包装 & 定制

加入购物车

实验操作小课堂

资源下载

重组蛋白用户指南

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品信息

生物活性	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
产品描述	A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.
种属	Cynomolgus
表达系统	HEK293 Cells
标签	C-His
蛋白编号	A0A2K5X4X8
别名	Mltng,mKIAA0021,Meltrin-γ,Meltrin-gamma,Mdc9,MCMP,Kiaa0021,CORD9,AU020942,Adam9,ADAM 9
蛋白构建	Ala29-Gly698
蛋白纯度	> 90% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
分子量	74.90 kDa (predicted). The protein migrates to 65-115 kDa based on Tris-Bis PAGE result.
内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
存储	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.